Four premature infants developed apnoeas severe enough to warrant resuscitation after immunisation with diphtheria, pertussis, and tetanus (DPT), and Haemophilus influenzae B (Hib). One required re-intubation and ventilation.
immunised with his first course of DTP and Hib. Within 48 hours he went oV his feeds, became tachypnoiec, and sustained several apnoeic episodes with recorded drops in O 2 saturations. These required treatment with facial O 2 and suction, but settled over 24 hours. His second and third immunisations given a month apart were uneventful.
Case 4 was a boy born at 27+6 weeks of gestational age, and weighing 900 g. He was ventilated for 5 weeks, developing recurrent pneumothoraces. A PDA was closed with indomethacin. He developed intraventricular haemorrhages and haemorrhagic hydrocephalus requiring a ventriculo-peritoneal shunt insertion. In the weeks leading up to immunisation he had only the occasional apnoea and bradycardia. He was immunised with his first course of DTP and Hib at a corrected gestational age of 42 weeks. Within 12 hours he was having multiple profound apnoeas, bradycardias, and desaturations, requiring resuscitation with bag and mask ventilation. These settled the following day. Six weeks later he received his second course of DTP and Hib without any adverse eVect.
Discussion
It is common practice in neonatal units to immunise premature infants with DTP and Hib at around eight weeks after delivery. Although the occurrence of apnoeic episodes in premature babies immunised at eight weeks is recognised, it has not been well documented in the UK. Indeed, the most recent UK study did not look at apnoea as an adverse event.
1 In Australia and North America one retrospective and two prospective studies, 2-4 estimated the risk of apnoea after immunisation in premature infants at between 17-23%. Most episodes were clinically insignificant. Some episodes, however, may be profound enough to require respiratory support. The presumed cause is the pertussis component.
Two studies 2 4 suggested that those infants more at risk of apnoea tend to be of a lower gestation and birthweight, require ventilation for longer, and are more likely to have chronic lung disease. One study 3 showed no significant diVerence between those infants who had apnoeas and those who did not.
It is clear from our experience that some premature infants are at risk of life threatening apnoea after immunisation. During the period in which these cases occurred, we immunised a total of 51 infants of a similar gestational age. The risk of severe apnoea may, therefore, be as high as 8% in those infants born at less than 30 weeks of gestation. We believe that further, larger studies are needed to show the exact risk to these smaller infants. It would be interesting to know if the risk could be reduced by using the acellular pertussis vaccine. Depending on the outcome of these trials, it may be necessary to delay immunisation in extremely low birthweight infants.
